On May 9, 2014, Amicus Therapeutics, Inc. (NASDAQ:FOLD) updated its Investor Presentation for the Migalastat Monotherapy Program (the “Presentation”). The Company’s Chief Financial Officer, William D. Baird III and the Company’s Chief Operating Officer, Bradley L. Campbell, will present some or all of this Presentation to various investors in the coming months. A copy of the presentation materials is attached hereto as Exhibit 99.1. Amicus … Continue reading Biotech Decliners: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Relypsa Inc (NASDAQ:RLYP), Receptos Inc (NASDAQ:RCPT), TG Therapeutics, Inc. (NASDAQ:TGTX), Chimerix Inc (NASDAQ:CMRX)